

## Immunic to Participate in Scientific and Industry Conferences in May

**NEW YORK, May 2, 2025 – [Immunic, Inc.](#) (Nasdaq: IMUX)**, a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following scientific and industry conferences in May:

- **May 3-6: Digestive Disease Week (DDW).** Two abstracts discussing Immunic’s phase 1/1b clinical trial of IMU-856, an orally available and systemically acting small molecule modulator that targets SIRT6 (Sirtuin 6), in patients with celiac disease, have been accepted for poster presentations at this conference in San Diego, CA.
  - **Poster Title:** *IMU-856 vs. Placebo Efficacy Effects in Celiac Disease Patients Are Independent of Q-MARSH Scale at Baseline*
  - **Abstract ID:** 4216653
  - **Poster Number:** Tu1329
  - **Presenting Author:** Indira Pichetto Olanda, M.D., Associate Medical Manager, Immunic
  - **Session:** Enteropathies — Celiac, Gluten Related and Environmental
  - **Session Date:** Tuesday, May 6, 2025
  - **Session Time:** 12:30 – 1:30 pm PDT
  
  - **Poster Title:** *Influence of Gut Epithelial Condition on the Pharmacokinetic Properties of IMU-856, an Oral Regulator of Barrier Function for the Treatment of Celiac Disease*
  - **Abstract ID:** 4219364
  - **Poster Number:** Tu1344
  - **Presenting Author:** Jacques Arend, M.D., Head of Clinical Pharmacology, Immunic
  - **Session:** Enteropathies — Celiac, Gluten Related and Environmental
  - **Session Date:** Tuesday, May 6, 2025
  - **Session Time:** 12:30 – 1:30 pm PDT
  
- **May 13-15: Clinical Trial Supply Forum 2025.** Kimi Oanh Le, Head of Clinical Trial Supply at Immunic, will discuss the clinical trial supply chain challenges working across the Middle East and North Africa (MENA) at this forum in Brussels, Belgium.
  - **Presentation Type:** Case Study
  - **Case Study Title:** Immunic Therapeutics Supply Chain Challenges Working Across MENA
  - **Date:** Wednesday, May 14, 2025
  - **Time:** 10:40 am CEST (4:40 am EDT)
  
- **May 28-31: Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting 2025.** Members of Immunic’s management, medical and preclinical teams will attend this meeting in Phoenix, AZ. The team will be available throughout the event at booth #911. Additionally, preclinical data highlighting lead asset, nuclear receptor-related 1 (Nurr1) activator, vidofludimus calcium (IMU-838), will be presented in a poster presentation.
  - **Poster Title:** *In Preclinical Models, Vidofludimus Calcium Exhibits Potential Neuroprotective Effects in Multiple Sclerosis by Modulating Nurr1*

- **Presenting Author:** Amelie Schreieck, Ph.D., Senior Manager Biomarker Development, Immunic
- **Abstract ID:** 10271
- **Poster Board Label:** NDM01
- **Date:** Thursday, May 29, 2025
- **Time:** 5:00 – 7:00 pm MST

All presentations will be accessible on the “Events and Presentations” section of Immunic’s website at: <https://ir.imux.com/events-and-presentations>.

#### **About Immunic, Inc.**

Immunic, Inc. (Nasdaq: IMUX) is a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. The company’s lead development program, vidofludimus calcium (IMU-838), is currently in phase 3 clinical trials for the treatment of relapsing multiple sclerosis, which are expected to be completed in 2026. It has already shown therapeutic activity in phase 2 clinical trials in patients suffering from relapsing-remitting multiple sclerosis and progressive multiple sclerosis. Vidofludimus calcium combines neuroprotective effects, through its mechanism as a first-in-class nuclear receptor related 1 (Nurr1) activator, with additional anti-inflammatory and anti-viral effects, by selectively inhibiting the enzyme dihydroorotate dehydrogenase (DHODH). IMU-856, which targets the protein Sirtuin 6 (SIRT6), is intended to restore intestinal barrier function and regenerate bowel epithelium, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease as well as inflammatory bowel disease, Graft-versus-Host-Disease and weight management. IMU-381, which currently is in preclinical testing, is a next generation molecule being developed to specifically address the needs of gastrointestinal diseases. For further information, please visit: [www.imux.com](http://www.imux.com).

#### **Cautionary Statement Regarding Forward-Looking Statements**

This press release contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, sufficiency of cash and cash runway, expected timing, development and results of clinical trials, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to management’s and employee’s participation in scientific and industry conferences. Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management’s current expectations and involve substantial risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, increasing inflation, tariffs and macroeconomics trends, impacts of the Ukraine – Russia conflict and the conflict in the Middle East on planned and ongoing clinical trials, risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient financial and other resources to meet business objectives and operational requirements, the fact that the results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial results, any changes to the size of the target markets for the Company’s products or product candidates, the protection and market exclusivity provided by Immunic’s intellectual property, risks related to the drug development and



the regulatory approval process and the impact of competitive products and technological changes. A further list and descriptions of these risks, uncertainties and other factors can be found in the section captioned "Risk Factors," in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC on March 31, 2025, and in the company's subsequent filings with the SEC. Copies of these filings are available online at [www.sec.gov](http://www.sec.gov) or [ir.imux.com/sec-filings](http://ir.imux.com/sec-filings). Any forward-looking statement made in this release speaks only as of the date of this release. Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all of the contents of this press release.

## **Contact Information**

### **Immunic, Inc.**

Jessica Breu

Vice President Investor Relations and Communications

+49 89 2080 477 09

[jessica.breu@imux.com](mailto:jessica.breu@imux.com)

### **US IR Contact**

Rx Communications Group

Paula Schwartz

+1 917 633 7790

[immunic@rxir.com](mailto:immunic@rxir.com)

### **US Media Contact**

KCSA Strategic Communications

Caitlin Kasunich

+1 212 896 1241

[ckasunich@kcsa.com](mailto:ckasunich@kcsa.com)